Carnegie Capital Asset Management, LLC Incyte Corp Transaction History

Carnegie Capital Asset Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 13, 2022	BUY	$66.18 - $83.18 $175,377 - $220,427	2,650 New	2,650 $223,000
Q3 2021 Oct 08, 2021	SELL	$68.67 - $84.02 $181,975 - $222,653	-2,650 Closed	0 $0
Q1 2021 Apr 12, 2021	SELL	$76.02 - $100.5 $45,612 - $60,300	-600 Reduced 18.46%	2,650 $215,000
Q4 2020 Feb 08, 2021	BUY	$80.74 - $97.7 $48,444 - $58,620	600 Added 22.64%	3,250 $283,000
Q3 2020 Oct 13, 2020	BUY	$85.07 - $109.69 $225,435 - $290,678	2,650 New	2,650 $238,000

657

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.5B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Carnegie Capital Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Carnegie Capital Asset Management, LLC with notifications on news.